Design and development of new class of Mycobacterium tuberculosis l-alanine dehydrogenase inhibitors
作者:Rudraraju Srilakshmi Reshma、Shalini Saxena、Karyakulam Andrews Bobesh、Variam Ullas Jeankumar、Saritha Gunda、Perumal Yogeeswari、Dharmarajan Sriram
DOI:10.1016/j.bmc.2016.07.051
日期:2016.9
l-AlaDH) is one of the important drug targets for treating latent/persistent tuberculosis. In this study we used crystal structure of the MTB l-AlaDH bound with cofactor NAD+ as a structural framework for virtual screening of our in-house database to identified new classes of l-AlaDH inhibitor. We identified azetidine-2,4-dicarboxamide derivative as one of the potent inhibitor with IC50 of 9.22+/-0.72muM
结核分枝杆菌丙氨酸脱氢酶(MTB 1-AlaDH)是治疗潜伏性/持续性结核病的重要药物靶标之一。在这项研究中,我们使用与辅因子NAD +结合的MTB 1-AlaDH的晶体结构作为对内部数据库进行虚拟筛选的结构框架,以鉴定出新的I-AlaDH抑制剂类别。我们鉴定出氮杂环丁烷-2,4-二甲酰胺衍生物是一种有效的抑制剂,IC50为9.22 +/-0.72μM。通过合成进行的进一步先导最优化导致化合物1-(异烟酰胺基)-N2,N4-双(苯并[d]噻唑-2-基)氮杂环丁烷-2,4-二甲酰胺(18),l-AlaDH IC50为3.83 +/-营养不良的休眠MTB模型降低0.12μM,营养减少2.0log,主动复制MTB的MIC降低11.81μM。